High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma

Area of Science:

• Oncology
• Urology
• Molecular Biology

Background:

• Prostate cancer (PCa) lacks effective therapies, driving research for novel antigenic targets.
• Placenta-specific 1 (PLAC1), a cancer-testis antigen, shows ectopic expression in various tumors.
• Investigating PLAC1 in PCa offers potential for new therapeutic strategies.

Purpose of the Study:

• To examine the differential expression of Placenta-specific 1 (PLAC1) in prostate cancer (PCa) tissues.
• To correlate PLAC1 expression with clinicopathological parameters and prostate-specific antigen (PSA) levels.

Main Methods:

• Microarray-based immunohistochemistry was used to analyze PLAC1 expression in 227 prostate tissue samples.
• Samples included PCa, high-grade prostatic intraepithelial neoplasia (HPIN), benign prostatic hyperplasia (BPH), and normal prostate tissues.
• Correlation analyses were performed between PLAC1, Gleason score, and PSA expression.

Main Results:

• PLAC1 expression increased progressively from BPH to PCa, with minimal detection in normal tissues.
• PLAC1 expression positively correlated with Gleason score (p ≤ 0.001).
• A negative correlation was observed between PLAC1 and PSA expression in PCa and HPIN (p ≤ 0.01).
• Increased PLAC1 expression significantly elevated the odds of PCa and HPIN diagnosis (OR 49.45).

Conclusions:

• PLAC1 is differentially expressed in PCa, showing higher levels in cancerous tissues.
• The positive association with Gleason score and negative correlation with PSA suggest PLAC1's role in PCa progression.
• PLAC1 shows promise as a biomarker and potential target for advanced PCa therapies.